LONDON – The cannabis-based drug specialist GW Pharma plc has filed for a listing on Nasdaq, with the ambition of raising up to $50 million to turbo-charge development of its preclinical pipeline and expand manufacturing capacity in anticipation of the U.S. launch of its lead product Sativex.
Read More
LONDON – The genome of the tapeworm has been sequenced, providing researchers with a panoply of genes that may provide new targets for treatment of those parasites. Scientists hope that, by identifying tapeworm genes that are similar to human genes, it may be possible to select candidate drugs that are already approved for use against other conditions, such as cancer.
Read More
AstraZeneca plc is once again taking the ax to its R&D operations, announcing plans to relocate 2,500 roles and cut about 1,600 jobs, mainly in the UK and U.S., as it consolidates discovery and development in Cambridge, UK; Gaithersburg, Maryland; and Mölndal, near Gothenburg, in Sweden.
Read More
Start-up Helmedix Pty Ltd. has raised A$1.25 million (US$1.29 million) in seed funding, providing a springboard to the commercialization of molecules based on immune-modulating peptides used by helminth parasites to suppress the immune response of their hosts. Read More
India's Drug and Cosmetics Act purports to keep clinical trials kosher under something called Schedule Y, but the law – which has not been amended since 2005 – lacks rules for mandatory practice and does not specify what recourse trial participants have when things go wrong.
Read More
ThromboGenics NV is banking a €45 million (US$58.8 million) milestone payment from its partner, Alcon, a unit of Novartis AG, following formal European Union (EU) approval for Jetrea (ocriplasmin) for treating patients with vitreomacular traction (VMT), including those with a macular hole up to 400 microns in diameter.
Read More
Sinovac Biotech Ltd.'s enterovirus 71 (EV71) vaccine looks good in preliminary results from Phase III data assessing efficacy, immunogenicity and safety against hand, foot and mouth disease.
Read More
• BioLineRx Ltd., of Jerusalem, said it received approval from French regulators to start a Phase I/II trial of BL-8020, an oral, interferon-free treatment for hepatitis C virus (HCV).
Read More
